


Supporting Information

COVID-19 in an adolescent with aplastic anemia undergoing immunosuppressive therapy: a case report and details of antibody testing for SARS-CoV-2


Shota Kato *et al.*



SUPPLEMENTAL FIGURE S1 Clinical course of the patient


Clinical course including treatment, absolute neutrophil, and lymphocyte counts is illustrated. Each bar and point represent the period and timing in which drugs or blood transfusion were administered.

ALC, absolute lymphocyte count; ANC, absolute neutrophil count; CS, corticosteroids; CyA, cyclosporine; EPAG, eltrombopag; rATG, rabbit antithymocyte globulin; RBC, red blood cell transfusion; Plt, platelet transfusion



SUPPLEMENTAL FIGURE S2 Peripheral blood counts before and after COVID-19

(A) white blood cell count (WBC), (B) absolute neutrophil count (ANC), (C) absolute lymphocyte count (ALC), (D) hemoglobin (Hb), and (E) platelet count (Plt).



SUPPLEMENTAL FIGURE S3 Titers of anti-SARS-CoV-2 antibodies of the present case compared to those of other patients with COVID-19

The shaded regions indicate the 95% confidence intervals of anti-SARS-CoV-2 antibody levels of the 137 patients with COVID-19 in the University of Tokyo Hospital, a part of which was previously reported.¹⁶ Lower limits of the 95% confidence intervals less than 0 AU/mL were replaced by 0.1 AU/mL.

IgA, immunoglobulin A; IgG, immunoglobulin G, IgM immunoglobulin M, N, nucleocapsid protein; RBD, receptor-binding domain; S1, S1 subunit of spike protein; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2